Products
Platform
Research
Market
Learn
Partner
Support
IPO

A

Anthem Biosciences Share Price

593.85
-6.10 (-1.02%)
ANTHEM • 21 Jan, 2026 | 10:19 AM
Buywith MTF at 3.33x leverage
The current prices are delayed, login or Open Demat Account for live prices.

Anthem Biosciences Stock Performance

1W Return-4.65
1Y Return0.00
Today's Low588.95
Prev. Close599.95
Mkt Cap (Cr.)33,693.80
1M Return-12.53
3Y Return0.00
52-Week High873.5
Open599.95
PE Ratio56.38
6M Return-18.69
Today's High600.25
52-Week Low587.1
Face Value2

Anthem Biosciences Company background

Founded in: 2006
Anthem Biosciences Limited was originally incorporated as Anthem Biosciences Private Limited, dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to Anthem Biosciences Limited and a Certificate of Incorporation was issued by RoC on December 10, 2024.The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are highvalue products used in drug, agrochemical and speciality chemicals industries.The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007. It commenced discovery biology services with a fermentation capacity of 2 KL in 2008. It expanded the Custom Synthesis Plant at Unit I increasing its capacity from 6 KL to 24 KL in 2010. It set up a high potent lab at Unit I Bommasandra Facility in 2016. The Company was merged with Anthem Cellutions (India) Private Limited by acquiring 100% of its share capital in November, 2017. It set up a flow chemistry lab scale and solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. It commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL in 201819. In year 2020, Company started operations to biological unit 2 earmarked for a specific client. It expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL. In FY 2024, Company set up a wholly owned subsidiary Neoanthem Lifesciences Private Limited and commenced operations at Unit III for development in projects. Company launched the initial public offering of 59,575,319 equity shares of face value of Rs 2 each by raising funds through offer for sale aggregating to Rs 3395 Crore in July, 2025. The Company expanded the fermentation capacity to 140 KL at the Unit II in 2025.

Anthem Biosciences Financial Highlights


For the full year FY2025–2026, revenue reached ₹1930.28 crore and profit touched at ₹451.26 crore. As of Dec '25, Anthem Biosciences’s market capitalisation stood at ₹33,693.80 crores. Shareholding as of Dec '25 shows promoters holding 74.7%, with FIIs at 1.4%, DIIs at 7.6%, and public at 16.3%.

Anthem Biosciences Share Price Today


As of 21 Jan 2026, Anthem Biosciences share price is ₹593.8. The stock opened at ₹600 and had closed at ₹600 the previous day. During today’s trading session, Anthem Biosciences share price moved between ₹588.95 and ₹600.25, with an average price for the day of ₹594.60. Over the last 52 weeks, the stock has recorded a low of ₹587.10 and a high of ₹873.50. In terms of performance, Anthem Biosciences share price has increased by 4.2% over the past six months and has declined by 15.57% over the last year.
Read More
View details of Market Depth

Anthem Biosciences Fundamental

Market Cap (in crs)

33,693.80

Face Value

2

Turnover (in lacs)

413.73

Key Metrics

Qtr Change %
-18.3
Dividend yield 1yr %
0

Anthem Biosciences Key Financials

View more
Loading chart...
Anthem Biosciences Quarterly Revenue
Anthem Biosciences Yearly Revenue
Anthem Biosciences Quarterly Net Profit/Loss
Anthem Biosciences Yearly Net Profit/Loss

Anthem Biosciences Result Highlights

  • Anthem Biosciences Ltd reported a 6.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were down by 2.2% QoQ and - - YoY.

  • The net profit increased 27.7% QoQ and - - YoY.

  • The earnings per share (EPS) of Anthem Biosciences Ltd stood at 3.06 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Anthem Biosciences Shareholding Pattern

Promoter
74.7%
Foreign Institutions
1.4%
Mutual Funds
6.9%
Domestic Institutions
7.6%
Public
16.3%

Anthem Biosciences Technical Analysis

Moving Averages Analysis
593.85
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
13
Day EMA5
614.90
Day EMA10
624.50
Day EMA12
627.50
Day EMA20
636.60
Day EMA26
641.90
Day EMA50
661.70
Day EMA100
708.00
EMA
Delivery & Volume
Loading chart...

Day

46.30%

Week

48.70%

Month

49.40%

Delivery & Volume

601.02
Pivot
Resistance
First Resistance
614.93
Second Resistance
629.92
Third Resistance
643.83
Support
First Support
586.03
Second support
572.12
Third Support
557.13
Relative Strength Index
33.47
Money Flow Index
35.48
MACD
-14.44
MACD Signal
-11.02
Average True Range
19.80
Average Directional Index
31.13
Rate of Change (21)
-10.31
Rate of Change (125)
0.00
Compare

Anthem Biosciences Latest News

07 JAN 2026 | Wednesday
07 JAN 2026 | Wednesday
29 DEC 2025 | Monday

Please be aware that Anthem Biosciences stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account